IT’S TIME TO TEST MOSQUIRIX IN PALAWAN
IT’S TIME TO TEST MOSQUIRIX IN PALAWAN
To my surprise—and perhaps yours too—the Anopheles mosquito, the primary carrier of
malaria, is still very much alive and buzzing… in Palawan.
We often talk
about dengue and its deadly impact, but we forget that malaria is quietly lingering in the shadows. According to
recent data, 6,188 out of the 6,248 malaria
cases in the Philippines came from Palawan. That’s more than 99%. So, if we're going to act on malaria
at all, we clearly know where to start.
For those
unfamiliar with the disease: malaria is caused by Plasmodium parasites, spread through the bites of
infected female Anopheles mosquitoes. These parasites enter the bloodstream,
head for the liver, multiply, and eventually infect red blood cells—bringing
with them fever, chills, headaches,
and in severe cases, anemia, organ
failure, or even cerebral
malaria.
Now here’s
where the conversation gets more urgent—and hopeful.
There is a vaccine. It’s called Mosquirix (scientific name: RTS, S/AS01).
Developed by GlaxoSmithKline (GSK)
in collaboration with the PATH Malaria
Vaccine Initiative and supported in part by the Bill and Melinda Gates Foundation, Mosquirix has shown
promising results in African pilot programs. According online sources, the
vaccine reduces hospital admissions from
severe malaria by 30% and decreases
toddler deaths by 15%. And yet—despite those impressive numbers—it’s
not yet being used here in the Philippines.
Let me ask, why not?
I have searched
for any sign that our Food and Drug Administration (FDA) has been approached
for approval, either by GSK’s local office or by any interested government
entity. But there’s radio silence. Given the urgency and the focused need in
Palawan, one would expect at least a pilot
test or an application for
importation. Sadly, nothing so far.
What makes this
frustrating is that unlike during the COVID-19
pandemic, when we were forced to use hastily approved vaccines out of
desperation, Mosquirix has already gone
through years of trials and real-world testing. The World Health
Organization (WHO) itself has recommended
it for use in children in malaria-endemic areas. If that’s not a green
light, I don’t know what is.
So, let’s talk
action.
If Palawan is
the clear hotspot, then why not begin our pilot testing there? With the right coordination, this
can be done swiftly and effectively. The infrastructure exists: we have
regional hospitals, local government units, and even NGOs on the ground who are
used to working with public health programs. All we need is the political will and the bureaucratic coordination.
May I humbly
suggest a few steps?
·
Let’s start with GSK’s local office. Surely, they can
initiate the FDA application and coordinate with their UK headquarters.
·
Let’s involve Microsoft’s local office as well. While
they didn’t develop Mosquirix, they’re heavily invested in global health data
and public health analytics. They could help us connect with key
decision-makers or aid with vaccine tracking tools.
·
The Department of Health (DOH) can
immediately reach out to the WHO regional
office to align with international standards.
·
The Department of Foreign Affairs (DFA) can
instruct our embassies in London and
Washington D.C. to open lines with GSK and global health partners.
·
And of course,
the Department of Trade and Industry
(DTI) can offer regulatory guidance and incentives for private-public
collaboration.
Let me also
point out something we tend to overlook: the Philippines is a mosquito-prone country. We already know
about dengue and now malaria—but who knows what other mosquito-borne diseases
could surface in the future? Climate change, increased travel, and urbanization
are only raising the risks.
So I ask: why
not build a long-term national
mosquito-borne disease defense strategy, and let the Mosquirix pilot in Palawan be the first
test case?
If we move
decisively now, we can position the Philippines as a regional leader in tropical disease control—instead of
always playing catch-up. We’ve done it before in disaster response and digital
payments. Why not in public health?
In closing, let
me reiterate that inaction is also a
decision—and often a costly one. We have a tool. We have the data. We
have a clearly identified problem area. All that’s missing is for someone to
say: “Let’s begin.”
Let that someone be us.
Ramon Ike V. Seneres,
www.facebook.com/ike.seneres
iseneres@yahoo.com, 09088877282,
senseneres.blogspot.com
08-12-2025
Comments
Post a Comment